Marja Pyörälä

3.5k total citations
35 papers, 1.6k citations indexed

About

Marja Pyörälä is a scholar working on Hematology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Marja Pyörälä has authored 35 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 10 papers in Oncology and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Marja Pyörälä's work include Hematopoietic Stem Cell Transplantation (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Acute Myeloid Leukemia Research (7 papers). Marja Pyörälä is often cited by papers focused on Hematopoietic Stem Cell Transplantation (11 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers) and Acute Myeloid Leukemia Research (7 papers). Marja Pyörälä collaborates with scholars based in Finland, United States and Denmark. Marja Pyörälä's co-authors include Kalevi Pyörälà, Heikki Miettinen, Markku Laakso, Anne Forhan, É. Eschwège, Beverley Balkau, Martin Shipley, Pirjo Halonen, K Pyörälä and Mauri Laakso and has published in prestigious journals such as Circulation, Blood and Diabetes Care.

In The Last Decade

Marja Pyörälä

33 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marja Pyörälä Finland 11 922 421 311 301 215 35 1.6k
Sung Keun Park South Korea 22 484 0.5× 339 0.8× 135 0.4× 635 2.1× 217 1.0× 111 1.6k
Anthony J. Proudler United Kingdom 21 957 1.0× 491 1.2× 188 0.6× 382 1.3× 327 1.5× 34 1.9k
Ken Williams United States 11 771 0.8× 301 0.7× 545 1.8× 439 1.5× 274 1.3× 13 1.6k
Eiji Oda Japan 22 392 0.4× 323 0.8× 291 0.9× 451 1.5× 240 1.1× 75 1.3k
Barbara Głowińska‐Olszewska Poland 17 443 0.5× 237 0.6× 127 0.4× 199 0.7× 145 0.7× 101 1.2k
Halil Önder Ersöz Türkiye 19 621 0.7× 165 0.4× 148 0.5× 139 0.5× 92 0.4× 56 1.2k
Andromachi Vryonidou Greece 22 805 0.9× 283 0.7× 292 0.9× 293 1.0× 181 0.8× 67 1.9k
Carl-Göran Ericsson Sweden 18 306 0.3× 374 0.9× 257 0.8× 408 1.4× 172 0.8× 22 1.3k
Dimitrios Patoulias Greece 22 674 0.7× 547 1.3× 283 0.9× 176 0.6× 153 0.7× 211 1.6k
Morton G. Burt Australia 22 1.1k 1.2× 249 0.6× 175 0.6× 301 1.0× 148 0.7× 59 1.7k

Countries citing papers authored by Marja Pyörälä

Since Specialization
Citations

This map shows the geographic impact of Marja Pyörälä's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marja Pyörälä with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marja Pyörälä more than expected).

Fields of papers citing papers by Marja Pyörälä

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marja Pyörälä. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marja Pyörälä. The network helps show where Marja Pyörälä may publish in the future.

Co-authorship network of co-authors of Marja Pyörälä

This figure shows the co-authorship network connecting the top 25 collaborators of Marja Pyörälä. A scholar is included among the top collaborators of Marja Pyörälä based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marja Pyörälä. Marja Pyörälä is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeidan, Amer M., Anthony S. Stein, Johanna Rimpiläinen, et al.. (2025). Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study. Blood. 146(Supplement 1). 236–236. 1 indexed citations
2.
3.
Kontro, Mika, Anthony S. Stein, Marja Pyörälä, et al.. (2024). Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study. Blood. 144(Supplement 1). 4265–4265. 1 indexed citations
4.
Kontro, Mika, Anthony S. Stein, Marja Pyörälä, et al.. (2023). Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies. Blood. 142(Supplement 1). 2915–2915. 2 indexed citations
5.
6.
Ruokoranta, Tanja, Joseph Saad, Monica Hellesøy, et al.. (2023). Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia. Blood. 142(Supplement 1). 2927–2927.
7.
Hohtari, Helena, Niels Pallisgaard, Matti Kankainen, et al.. (2022). Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 107(8). 1971–1976. 1 indexed citations
8.
Partanen, Anu, Outi Kuittinen, Marja Pyörälä, et al.. (2021). Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma. Journal of Hematology. 10(6). 246–254. 1 indexed citations
9.
Kuusanmäki, Heikki, Tanja Ruokoranta, Kimmo Porkka, et al.. (2021). Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial. Blood. 138(Supplement 1). 228–228. 1 indexed citations
10.
Partanen, Anu, Antti Ropponen, Outi Kuittinen, et al.. (2020). Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study. Leukemia & lymphoma. 61(9). 2082–2092. 11 indexed citations
11.
Hämäläinen, Sari, Kari Pulkki, Marja Pyörälä, et al.. (2020). Febrile neutropenia in patients with acute myeloid leukemia: Outcome in relation to qSOFA score, C‐reactive protein, and blood culture findings. European Journal Of Haematology. 105(6). 731–740. 8 indexed citations
12.
Partanen, Anu, Antti Ropponen, Kaija Vasala, et al.. (2017). Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly. Annals of Hematology. 96(11). 1897–1906. 7 indexed citations
13.
Niittyvuopio, Riitta, Jarno Tuimala, Marja Pyörälä, et al.. (2017). Platelet donor selection for HLA‐immunised patients; the impact of donor‐specific HLA antibody levels. Transfusion Medicine. 27(5). 375–383. 9 indexed citations
14.
Varmavuo, Ville, Antti Ropponen, Anne Nihtinen, et al.. (2015). Blood graft cellular composition and posttransplant recovery in non‐Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion. 55(10). 2358–2368. 18 indexed citations
15.
Jantunen, Esa, Taru Kuittinen, Eija Mahlamäki, et al.. (2011). Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. European Journal Of Haematology. 86(4). 299–304. 36 indexed citations
16.
Jantunen, Esa, Karri Penttilä, Marja Pyörälä, et al.. (2010). Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplantation. 46(2). 308–309. 20 indexed citations
17.
Pyörälä, Marja, Heikki Miettinen, Pirjo Halonen, Markku Laakso, & Kalevi Pyörälà. (2000). Insulin Resistance Syndrome Predicts the Risk of Coronary Heart Disease and Stroke in Healthy Middle-Aged Men. Arteriosclerosis Thrombosis and Vascular Biology. 20(2). 538–544. 288 indexed citations
18.
Balkau, Beverley, R. J. Jarrett, Kalevi Pyörälà, et al.. (1998). High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care. 143 indexed citations
19.
20.
Pyörälä, Marja, Heikki Miettinen, Markku Laakso, & Kalevi Pyörälà. (1998). Hyperinsulinemia and the Risk of Stroke in Healthy Middle-Aged Men. Stroke. 29(9). 1860–1866. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sung Keun Park Breakdown of academic impact, for papers by Anthony J. Proudler Breakdown of academic impact, for papers by Ken Williams Breakdown of academic impact, for papers by Eiji Oda Breakdown of academic impact, for papers by Barbara Głowińska‐Olszewska Breakdown of academic impact, for papers by Halil Önder Ersöz Breakdown of academic impact, for papers by Andromachi Vryonidou Breakdown of academic impact, for papers by Carl-Göran Ericsson Breakdown of academic impact, for papers by Dimitrios Patoulias Breakdown of academic impact, for papers by Morton G. Burt
Rankless by CCL
2026